AbCellera Biologics Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
AbCellera Biologics Inc. (ABCL) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $32.00 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2025-02-27
- AbCellera Biologics Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2024-09-30 was $32.00M.
- AbCellera Biologics Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2024-06-30 was $32.00M.
- AbCellera Biologics Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $8.40M.
- AbCellera Biologics Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|
| 2024-09-30 | $32.00M 10-Q · filed 2024-11-04 | $64.00M derived: sum of 2 quarters · filed 2024-11-04 | |
| 2024-06-30 | $32.00M 10-Q · filed 2024-11-04 | ||
| 2022-12-31 | $8.40M 10-K · filed 2025-02-27 | ||
| 2021-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |